<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007978.ref020">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Modjarrad</surname>
   <given-names>K</given-names>
  </name>, 
  <name>
   <surname>Lin</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>George</surname>
   <given-names>SL</given-names>
  </name>, 
  <name>
   <surname>Stephenson</surname>
   <given-names>KE</given-names>
  </name>, 
  <name>
   <surname>Eckels</surname>
   <given-names>KH</given-names>
  </name>, 
  <name>
   <surname>De La Barrera</surname>
   <given-names>RA</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials</article-title>. 
  <source>Lancet</source>. 
  <year>2018</year>;
  <volume>391</volume>(
  <issue>10120</issue>):
  <fpage>563</fpage>â€“
  <lpage>571</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33106-9</pub-id>
  <?supplied-pmid 29217375?>
  <pub-id pub-id-type="pmid">29217375</pub-id>
 </mixed-citation>
</ref>
